	US 11,725,187 B2
	Selection of human hematopoetic stem cells using EPCR
Guy Sauvageau, Montréal (CA); Iman Fares, Boston, MA (US); and Jalila Chagraoui, Montreal (CA)
Assigned to UNIVERSITE DE MONTREAL, Montreal (CA)
Appl. No. 16/99,551
Filed by UNIVERSITE DE MONTREAL, Montréal (CA)
PCT Filed May 31, 2017, PCT No. PCT/CA2017/050661 § 371(c)(1), (2) Date Nov. 7, 2018, PCT Pub. No. WO2017/205977, PCT Pub. Date Dec. 7, 2017.
Claims priority of provisional application 62/344,011, filed on Jun. 1, 2016.
Prior Publication US 2019/0085291 A1, Mar. 21, 2019
Int. Cl. C12N 5/0789 (2010.01); A61K 35/28 (2015.01); A61K 35/14 (2015.01); C07K 14/74 (2006.01); C12M 3/06 (2006.01); G01N 33/569 (2006.01); C12N 15/113 (2010.01); A61K 35/51 (2015.01)

CPC C12N 5/0647 (2013.01) [A61K 35/14 (2013.01); A61K 35/28 (2013.01); C07K 14/70539 (2013.01); C12M 3/06 (2013.01); C12N 15/1138 (2013.01); G01N 33/56966 (2013.01); A61K 35/51 (2013.01); C12N 2501/50 (2013.01); C12N 2501/599 (2013.01); G01N 33/569 (2013.01)]

13 Claims

1. A method of expanding ex vivo human hematopoietic stem and/or progenitor cells, the method comprising:

a) stimulating a starting population of human stem and/or progenitor cells with a cell expanding factor selected from UM171 or analogues thereof, UM171 and UM729, or UM171 and lenalidomide, wherein the expression of Endothelial Protein C Receptor (EPCR) is increased in said stimulated starting population of stem and/or progenitor cells;

b) selecting a population of EPCR⁺ cells from the stimulated starting population of stem and/or progenitor cells; and

c) culturing the selected EPCR⁺ cells thereby expanding said EPCR⁺ cells.